Changes in circulating lymphocyte subpopulations in pigs receiving therapeutic doses of ceftiofur and tulathromycin
References
- 1. Altunok V., Yazar E., Elmas M., Traş B., Baş A.L., Cöl, R.: Investigation of haematological and biochemical side effects of tilmicosin in healthy New Zealand rabbits. J Vet Med Series B 2002, 49, 68-70.
- 2. Bazzoni F., Beutler B.: The tumor necrosis factor ligand and receptor families. New Engl J Med 1996, 334, 1717-1725.
- 3. Bergeron Y., Ouellet N., Deslauriers A.M., Simard M., Olivier M., Bergeron M.G.: Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice. Antimicrob Agents Chemother 1998, 42, 2527-2533.
- 4. Chang C.F., Chang L.C., Chang Y.F., Chen M., Chiang T.S.: Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine. J Vet Diagn Invest 2002, 14, 153-157.
- 5. Chrząstek K., Madej J.P., Mytnik E., Wieliczko A.: The influence of antibiotics on B-cell number, percentage, and distribution in the bursa of Fabricius of newly hatched chicks. Poult Sci 2011, 90, 2723-2729.
- 6. Chrząstek K., Wieliczko A.: The influence of enrofloxacin, florfenicol, ceftiofur and E. coli LPS interaction on T and B cells subset in chicks. Vet Res Commun 2015, 39, 53-60.
- 7. Ci X., Li H.Y., Song Y., An Y., Yu Q., Zeng F., Deng X.: Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice. Inflammation 2008, 31, 422-427.
- 8. Clinical and Laboratory Standards Institute. Reference leukocyte (WBC) differential count (proportional) and evaluation of instrument methods; Approved standard 2007, 27.
- 9. Committee for Veterinary Medicinal Products Summary Report: Ceftiofur. The European Agency for the Evaluation of Medicinal Products EMEA/CVMP/80785/2006-Final.
- 10. Committee for Veterinary Medicinal Products Summary Report: Tulathromycin. The European Agency for the Evaluation of Medicinal Products EMEA/MRL/842/2002-Final.
- 11. Duquette S.C., Fischer C.D., Williams A.C., Sajedy S., Feener T.D., Bhargava A., Reti K.L., Muench G.P., Morck D.W., Allison J., Lucas M.J., Buret A.G.: Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs. Am J Vet Res 2015, 76, 507-519.
- 12. Er A., Altan F., Cetin G., Dik B., Elmas M., Yazar E.: Assessment of the cardiotoxicity of tulathromycin in rabbits. Acta Vet Hung 2011, 59, 327-335.
- 13. Evans N.A.: Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease. Vet Ther 2005, 6, 83-95.
- 14. Fernandez Filho T., Favaro C Jr., Ingberman M., Beirao B.C.B., Inoue A., Gomes L., Caron L.F.: Effect of spray Escherichia coli vaccine on the immunity of poultry. Avian Dis 2013, 57, 671-676.
- 15. Fischer C.D., Beatty J.K., Duquette S.C., Morck D.W., Lucas M.J., Buret A.G: Direct and indirect anti-inflammatory effects of tulathromycin in bovine macrophages: inhibition of CXCL-8 secretion, induction of apoptosis, and promotion of efferocytosis. Antimicrob Agents Chemother 2013, 57, 1385-1393.
- 16. Fischer C.D., Beatty J.K., Zvaigzne C.G., Lucas M.J., Buret A.G.: Anti-inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-kappaB signaling and CXCL8 transcription. Antimicrob Agents Chemother 2011, 55, 338-348.
- 17. Hao Z., Zhao Y., Wu H., Hao L., Ding Z., Yang F., Qu B.: The physiological and biochemical evaluation of tulathromycin premix in pigs. J Anim Vet Adv 2012, 11, 4161-4166.
- 18. Mangano K., Quattrocchi C., Aiello C., Scalia G., Speciale A., Nicoletti G., Di Marco R.: Immunomodulatory properties of cefaclor: in vivo effect on cytokine release and lymphoproliferative response in rats. J Chemother 2006, 18, 641-647.
- 19. Nutsch R.G., Hart F.J., Rooney K.A., Weigel D.J., Kilgore W.R., Skogerboe T.L.: Efficacy of tulathromycin injectable solution for the treatment of naturally occurring swine respiratory disease. Vet Ther 2005, 6, 214-224.
- 20. Pomorska-Mól M., Pejsak Z.: Effect of therapeutic doses of enrofloxacin on circulating lymphocyte subpopulations in pigs. Bull Vet Inst Pulawy 2015, 59, 287-293.
- 21. Pomorska-Mól M., Czyżewska-Dors E., Kwit K., Wierzchosławki K., Pejsak Z.: Ceftiofur hydrochloride affects the humoral and cellular immune response in pigs after vaccination against swine influenza and pseudorabies. BMC Vet Res 2015, 11, 268.
- 22. Pomorska-Mól M., Kwit K., Wierzchosławki K., Dors A., Pejsak Z.: The effect of amoxicillin, ceftiofur, doxycycline, tiamulin and tulathromycin on swine humoral immune response induced by erysipelas vaccination. Vet Rec 2016, 178, 559.
- 23. Pomorska-Mól M., Czyżewska-Dors E., Kwit K., Pejsak Z.: Enrofloxacin decreases IL-6 and TNF-á production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells. J Vet Res 2016 60, 189-193.
- 24. Ratzinger F., Haslacher H., Poeppl W., Hoermann G., Kovarik J.J., Jutz S., Steinberger P., Burgmann H., Pickl W.F., Schmetterer KG.: Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep 2014, 4, 7438.
- 25. Villiger P.M., Cronin M.T., Amenomori T., Wachsman W., Lotz M.: IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. J Immunol 1991, 146, 550-559.
DOI: https://doi.org/10.1515/jvetres-2016-0071 | Journal eISSN: 2450-8608
Language: English
Page range: 481 - 487
Submitted on: Aug 1, 2016
Accepted on: Nov 7, 2016
Published on: Dec 17, 2016
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2016 Ewelina Czyżewska-Dors, Krzysztof Kwit, Zygmunt Pejsak, Małgorzata Pomorska-Mól, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.